Today, on 3rd April 2025, Aurobindo Pharma’s shares, among other Indian pharmaceutical companies, shot up since the opening bell. The sudden surge followed Trump’s announcement that the US would refrain from imposing reciprocal tariffs on Indian drugs and pharmaceutical companies (at least for now).
The White House fact sheet confirmed this and also showed that a few other products already under pressure from other tariffs are not included.
Following this declaration, the pharmaceutical companies largely invested in the US market, including Aurobindo Pharma, witnessed a 3-13% hike in their share prices.
Today, the pharma company’s shares opened to the market at Rs. 1,229.00, and the prices are currently up by 4% compared to the last session’s close of Rs. 1,157.85.
Aurobindo Pharma Share Price in Today’s Market
At 10 a.m., Aurobindo Pharma traded its shares for Rs. 1,209.05. It is nearly 1% lower than the opening rate. And 4.5% higher than its previous close. The company recorded a day-high trade of Rs. 1,267.30, almost 9% higher than the last close. According to the reports and estimates on Money Control, the current market capitalization shows 70,236 cores; the UC Limit is 1,209.05, and the LC Limit is 1,273.60.
Company Financials
During the third quarter of the 2024-20 fiscal year, Aurobindo Pharma reported an 8.5% gain in their revenue from operations. The value stood at Rs. 7,979 crore compared to the previous third quarter’s Rs. 7,352 Crore. Its net profit recorded Rs. 846 crores, 10% down from last year’s Rs. 9,40 Crores.
The US formulation’s revenue saw a 2.3% decline due to lower transient product sales. Meanwhile, the European formulations segment grew by 22.7%.
Recent News About Aurobindo Pharma
- In February 2025, Aurobindo Pharma revealed that the company plans to commence supplies to Europe from its China facility starting in April 2025.
- In March 2025, the US Court of Appeals for the Federal Circuit issued its ruling in the case of Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc.
Aurobindo Pharma Share Price Target
According to experts’ calculations on Trendlyne, Aurobindo Pharma Ltd. has an average target of 1501. The consensus estimated an upside of 22.73% from the last price of 1223.
Should You Buy, Sell, Or Hold?
Most analysts on Trendlyne support buying and holding the shares, with majority votes to buy. On MoneyControl, 61% of market analysts suggest buying, 11% suggest selling, and 7% recommend holding the shares. But, before investing in the business, consider its long-term performance and consult your analyst to make the perfect move.
